论文部分内容阅读
目的研究高危型人乳头状瘤病毒(HPV)感染在宫颈鳞癌患者同步放化疗前后阳性率变化,以及对引发宫颈鳞癌的主要高危型HPV亚型的探讨。方法对2012年2月-2014年2月收治的278例患者按照数学随机抽选的方式选取94例进行同步放化疗,在治疗前后10个月,采集宫颈内脱落细胞并检测计算其高危型HPV的阳性率;在入院时已确诊为高危型HPV DNA阳性患者中随机抽选68例进行检测,分析其HPV亚型。结果94例患者中治疗前HPV-DNA阳性90例,其中高危型高达86例,阳性率为91.5%;在治疗后10个月的94例患者复查中,4例阴性患者无改变仍为阴性,而86例高危型HPV-DNA阳性患者中有71例转阴,余15例仍为阳性且为高危型,经过治疗后高危型HPV-DNA阳性率仅为16.0%;在68例高危型HPV-DNA阳性患者的检查中发现HPV16和HPV18较高,分别占72.0%和13.2%。结论经过宫颈鳞癌同步放化疗高危型HPV-DNA阳性率明显降低,HPV16是引发宫颈鳞癌的主要高危型HPV亚型。
Objective To study the positive rate of high-risk human papillomavirus (HPV) infection in patients with cervical squamous cell carcinoma before and after concurrent chemoradiotherapy, and to explore the main high-risk HPV subtypes of cervical squamous cell carcinoma. Methods A total of 278 patients admitted from February 2012 to February 2014 were enrolled in this study according to the method of mathematical random selection. 94 cases were treated with concurrent chemoradiotherapy and 10 months before and after treatment. The exfoliated cells were collected and their high-risk HPV Of the positive rate; admitted to hospital has been diagnosed as high-risk HPV DNA-positive patients randomized 68 cases were detected and analyzed its HPV subtypes. Results Ninety-four patients were positive for HPV-DNA before treatment, of which 86 cases were high-risk, with a positive rate of 91.5%. Of the 94 patients who underwent 10-month follow-up, 4 of the 94 negative patients were still negative, Among 86 high-risk HPV-DNA positive patients, 71 were negative and 15 were still positive and high-risk. After treatment, the positive rate of high-risk HPV-DNA was only 16.0%. In 68 high-risk HPV- DNA positive patients found HPV16 and HPV18 higher examination, accounting for 72.0% and 13.2%. Conclusions The positive rate of high-risk HPV-DNA after concurrent chemoradiotherapy in cervical squamous cell carcinoma is significantly lower. HPV16 is the major high-risk HPV subtype that causes cervical squamous cell carcinoma.